本研究研究了闪烁剂量测定法与切伦科夫成像相结合，用于全乳放疗 (WBRT) 期间的体内剂量监测。鉴于最近观察到对侧乳房 (CB) 剂量过多，体内剂量测定 (IVD) 有助于确保准确的剂量输送并降低继发性癌症的风险。这项工作提出了传统 IVD 的快速、简化的替代方案，提供了相对于患者治疗区域的测量位置的直接可视化。10 名根据 IRB 批准的协议同意的 WBRT 患者通过闪烁剂量测定和始终在线的切伦科夫成像进行监测，他们的处理和 CB 为一到三个分数。闪烁体剂量计是 1 毫米厚、直径 15 毫米的小塑料盘，根据光激发光剂量计 (OSLD) 进行校准，以生成积分输出到剂量的转换，其中积分输出是通过自定义拟合算法在后处理中测量的。在先前的研究中，椎间盘已针对各种治疗条件（包括射束能量和治疗几何形状）进行了广泛的表征。评估了 N=44 次剂量测定测量，包括 22 次治疗的乳房和 22 次 CB 测量。经过积分输出-剂量校准后，体内闪烁体剂量计表现出高线性度 (R2=0.99)，所有患者的 OSLD 读数均呈配对。闪烁和 OSLD 剂量测量之间的差异平均为处方剂量的 2.8%，或绝对剂量差异约为 7 cGy。闪烁剂量测定与切伦科夫成像的集成为 WBRT 中的体内剂量验证提供了准确、快速的替代方案，从而规避了局限性传统点剂量计。相对于治疗区域可视化测量位置的另一个好处是，用户可以更好地理解结果，并可以检测高剂量梯度。未来的工作将探索该技术在更广泛的放射治疗中的适用性，旨在简化 IVD 实践。版权所有 © 2024。由 Elsevier Inc. 出版。

This study investigates scintillation dosimetry coupled with Cherenkov imaging for in vivo dose monitoring during whole breast radiotherapy (WBRT). Given recent observations of excess dose to the contralateral breast (CB), in vivo dosimetry (IVD) could help ensure accurate dose delivery and decrease risks of secondary cancer. This work presents a rapid, streamlined alternative to traditional IVD, providing direct visualization of measurement location relative to the treatment field on the patient.10 WBRT patients consented under an IRB-approved protocol were monitored with scintillation dosimetry and always-on Cherenkov imaging, on both their treated and CB for one to three fractions. Scintillator dosimeters, small plastic discs 1mm thick and 15mm in diameter, were calibrated against optically-stimulated luminescent dosimeters (OSLDs) to generate an integral output-to-dose conversion, where integral output is measured in post-processing through a custom fitting algorithm. The discs have been extensively characterized in a previous study for various treatment conditions including beam energy and treatment geometry.N=44 dosimetry measurements were evaluated, including 22 treated breast and 22 CB measurements. Following integral output-to-dose calibration, in vivo scintillator dosimeters exhibited high linearity (R2=0.99) with paired OSLD readings across all patients. The difference between scintillation and OSLD dose measurements averaged 2.8% of the prescribed dose, or an absolute dose difference of approximately 7 cGy.Integration of scintillation dosimetry with Cherenkov imaging offers an accurate, rapid alternative for in vivo dose verification in WBRT, circumventing the limitations of conventional point dosimeters. The additional benefit of visualizing measurement locations relative to the treatment field provides users an enhanced understanding of results and allows for detection of high dose gradients. Future work will explore the applicability of this technique across a broader range of radiotherapy treatments, aiming to streamline IVD practices.Copyright © 2024. Published by Elsevier Inc.